Evaluation of Paclitaxel in Patients With CLI and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty

Overview

The use of drug coated balloon (DCB) in patients with critical limb ischemia (CLI) and tissue loss has recently raised some concerns after the IN.PACT deep trial using paclitaxel coated balloon angioplasty in the tibial arteries was terminated. The investigators objective is to establish the safety and efficacy of drug coated balloon (DCB) for femoropopliteal occlusive disease in patients with critical limb ischemia (CLI) and tissue loss. The investigators objective is to establish the safety and efficacy of drug coated balloon (DCB) for femoropopliteal occlusive disease in patients with critical limb ischemia (CLI) and tissue loss.

Full Title of Study: “Evaluation of Paclitaxel in Patients With CLI (Critical Limb Ischemia) and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2022

Detailed Description

Although the association between the drug coated balloon (DCB) therapy and limb outcomes could not be clearly linked to the use of antiproliferative agents, the findings of paclitaxel crystals downstream of the treated lesions, although in small amounts, has raised concerns about the safety of such therapy in patients with critical limb ischemia (CLI) and tissue loss. These concerns, however, may not translate to patients with femoropopliteal occlusive disease as the amount of paclitaxel reaching the foot may be even smaller after being filtered by the calf musculature. Since the use of DCB angioplasty in the Superficial Femoral Artery (SFA) and popliteal has been shown to deliver significantly more durable outcomes compared to standard angioplasty alone, with reported primary patency rates of almost 90% at one year, this therapy may even be more needed in patients with tissue loss where prolonged patency is essential for wound healing.

Interventions

  • Device: Angiogram, Medtronic DCB (paclitaxel)/stent
    • Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Each participant will receive angiogram with DCB (drug coated balloon)/stenting with wound debridement. 50% of subjects will receive an Angiogram, Medtronic DCB (paclitaxel)/stent. Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
  • Device: Angiogram, Bard DCB (paclitaxel)/stent
    • Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. 50% of subjects will receive ‘Angiogram, Bard DCB (paclitaxel)/stent’ . Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.

Arms, Groups and Cohorts

  • Other: Critical Limb Ischemia (CLI) and Tissue Loss
    • Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Patients with CLI will receive either Angiogram, Medtronic DCB (paclitaxel)/stent or Angiogram, Bard DCB (paclitaxel)/stent

Clinical Trial Outcome Measures

Primary Measures

  • Wound Healing
    • Time Frame: 12 months
    • Percentage of participants with wound healing defined as > 50% area/volume reduction of baseline ulcer(s) in the treated leg at 1 year.
  • Amputation Free Survival
    • Time Frame: 12 months
    • Percentage of participants with a 1 year amputation free survival.

Secondary Measures

  • Primary Patency ( determine if vessel remains open)
    • Time Frame: 3, 6, 12 months
    • Prospective duplex ultrasound will be performed at the intervals listed to verify (primary and secondary) patency of targeted vessels. Assessment of severe restenosis and reinterventions will be determined
  • Rate of severe stenosis (narrowing) and reinterventions
    • Time Frame: 12 months
    • Severe stenosis (>50%) evaluated by Duplex ultrasound at 1,3,6 and 12 month intervals

Participating in This Clinical Trial

Inclusion Criteria

  • Patient population: all patients with CLI (critical limb ischemia) and tissue loss scheduled for endovascular intervention for femoral popliteal occlusive or multilevel disease. – Patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed an Ethical Committee approved consent form – Female patients of childbearing potential have a negative pregnancy test ≤7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation – Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb prior to the study procedure with Rutherford Category 5 or 6 – General Angiographic Inclusion Criteria – Single or multiple lesions with ≥70% diameter stenosis (DS) of different lengths in the SFA and/or popliteal arteries. – Iliac inflow or Tibial outflow interventions can be done at the discretion of the investigator with standard balloon Percutaneous Transluminal Angioplasty (PTA) Exclusion Criteria:

  • Patient unwilling or unlikely to comply with Follow-Up schedule – Aneurysm in the target vessel – Acute thrombus in the target limb – Sensitivity to Paclitaxel – Immunosuppressed patients (transplant, chemotherapy, etc.)

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 95 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rabih A. Chaer
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Rabih A. Chaer, Professor of Surgery – University of Pittsburgh
  • Overall Official(s)
    • Rabih A Chaer, MD, Principal Investigator, University of Pittsburgh

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.